[CAS NO. 62613-82-5] Oxiracetam
PRODUCTS SPECIFICATIONS [62613-82-5]
DESCRIPTION [62613-82-5]
Overview
| MDL | MFCD00242951 |
|---|---|
| Molecular Weight | 158.16 |
| Molecular Formula | C6H10N2O3 |
| SMILES | O=C(N)CN1C(CC(O)C1)=O |
Summary
Oxiracetam is a cyclic derivative of γ-aminobutyric acid ( GABA ) which has been commonly used as nootropic drug to treat cognitive impairments.
IC50 & Target
GABA receptor [1]
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04205565 | Nanjing Yoko Biomedical Co., Ltd. |
Craniocerebral Injury
|
November 8, 2017 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : ≥ 100 mg/mL ( 632.27 mM )
DMSO : 25 mg/mL ( 158.07 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.3227 mL | 31.6136 mL | 63.2271 mL |
| 5 mM | 1.2645 mL | 6.3227 mL | 12.6454 mL |
| 10 mM | 0.6323 mL | 3.1614 mL | 6.3227 mL |
Synonyms